Lead
US Defense Secretary Pete Hegseth has announced a new annual testosterone screening program for active-duty and reserve service members aged 30 and older, with voluntary testing for those under 30. The initiative, unveiled in a video posted to X, is designed to ensure troops have the "right testosterone levels" to operate at their "absolute best," Hegseth said, framing it as part of the department's effort to maintain the military's most decisive advantage: the "individual warfighter."
"This initiative, it's not about artificial enhancement," Hegseth said. "It's about restoring and optimising your natural capabilities, protecting your longevity, ensuring you have the biological foundation required to sustain the fight."
Coverage Comparison
Reporting on the announcement varied in its emphasis. ABC Australia highlighted the controversy surrounding the decision, focusing on criticism from Democratic lawmakers who linked it to Hegseth's opposition to transgender service members. Al Jazeera presented the announcement in a neutral context, emphasizing Hegseth's stated rationale and the program's integration into existing annual health assessments. The Guardian's coverage was more critical, focusing on warnings from medical professionals about potential risks of unnecessary or harmful treatment, and questioning the scientific basis for the mandate.
Key Claims
Hegseth's announcement follows a 2022 incident in which the death of a Navy SEAL recruit revealed widespread testosterone use among elite US soldiers. The Navy subsequently began a drug-testing program to screen for hormonal substances related to testosterone. Hegseth's new initiative adds testosterone screening to the periodic health assessment that troops already complete each year.
Treatment, including testosterone replacement therapy, would be voluntary, Hegseth said. The program aims to keep troops "strong, resilient and capable," and to ensure "maximum psychological and mental readiness" given the brutal nature of the modern battlefield.
Medical professionals have raised concerns. According to The Guardian, five of six men's health experts contacted for the story said they were puzzled by the announcement and worried it may lead to unnecessary or harmful treatment. Dr Kevin McVary, a urologist, noted that while patients report improvements in cognitive alertness and stamina when treated for low testosterone, the evidence is not concrete and comes from symptomatic patients.
The American Urological Association and the Endocrine Society advise testosterone supplementation only for patients with confirmed testosterone deficiency and symptoms, as reported by The Guardian. The FDA has revised testosterone labels to remove a warning of increased risks of heart attack or stroke.
Hegseth is not the first Trump administration official to address low testosterone. Health Secretary Robert F Kennedy Jr has spoken about injecting testosterone as part of his personal "anti-aging regimen" and has warned, without evidence, that American teenagers have "50% of the testosterone of a 65-year-old man," according to The Guardian.
Research published in the journal Social Science and Medicine found that young men are being aggressively targeted online by influencers and wellness companies promoting hormone tests and treatments, The Guardian reported.
Perspectives
Democratic lawmakers, including Senator Tammy Duckworth and Representative Chrissy Houlahan, criticized the announcement, linking it to Hegseth's opposition to transgender service members, as reported by ABC Australia and Al Jazeera.
Medical professionals, as highlighted by The Guardian, cautioned that the screening could lead to unnecessary treatment and questioned the lack of solid evidence demonstrating that mass screening would optimize combat readiness.
Hegseth and the Pentagon framed the initiative as essential for maintaining military readiness and supporting the individual warfighter, emphasizing that treatment is voluntary and aimed at natural capabilities.